Aytu BioPharma Q4 revenue beats analyst estimates on EXXUA sales

Aytu Biopharma

22/09/2026 21:17

Overview
US pharmaceutical firm's fiscal Q4 revenue rose 6.4%, beating analyst expectations
Company reported near break-even net loss for the quarter, improving from prior year

Outlook
Company expects EXXUA launch momentum to continue, with evolving prescribing and payer patterns
Company aims to build toward more consistent positive adjusted EBITDA levels during fiscal 2027
ADHD and Pediatric portfolios expected to provide financial stability to support EXXUA investment

Result Drivers
EXXUA LAUNCH - Q4 revenue was driven by the first full quarter of EXXUA sales, with management citing growing prescription volume and broadening adoption
ADHD PORTFOLIO - Sequential improvement in ADHD Portfolio revenue was attributed to higher units, improved gross-to-net economics, and stable performance across existing brands, despite generic competition
PEDIATRIC PORTFOLIO - Q4 Pediatric Portfolio revenue increased from the prior quarter as product availability normalized following a supply disruption

Company press release: ID:nACS9NkSPa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$16.11 mln
$12.28 mln (3 Analysts)
Q4 Net Loss
 
$15,000
 
Q4 Adjusted EBITDA
 
$490,000
 
Q4 Gross Profit
 
$10.41 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Aytu Biopharma Inc is $7.00, about 229.4% above its September 21 closing price of $2.13

Reuters Recommended Reads
Sept 21 - AnaptysBio Q2 collaboration revenue rises on higher Jemperli royalties
Sept 22 - Amgen's autoimmune drug succeeds in late-stage trial

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)